Medicare and Medicaid
Our work in Medicare and Medicaid
-
Sex, Race, and Age Differences in Prevalence of Dementia in Medicare Claims and Survey Data
This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.
-
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near‐universal access to Medicare at age 65 is associated with improvements in population‐level cancer mortality.
-
Adapting Medicare Advantage Bidding for COVID-19 Related Uncertainty on Claims: A Proposal
The COVID-19 pandemic is fundamentally disrupting the health care system and injecting significant uncertainty about current and future utilization and costs.
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Categorized in -
What Are the Health Coverage Provisions in the House Coronavirus Bill?
USC-Brookings Schaeffer Initiative experts break down the health coverage provisions in the latest House bill addressing the novel coronavirus.
Categorized in -
Association of Combination Statin and Antihypertensive Therapy With Reduced Alzheimer’s Disease and Related Dementia Risk
Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Categorized in -
The ACA’s Individual Mandate In Retrospect: What Did It Do, And Where Do We Go From Here?
A USC-Brookings Schaeffer Initiative expert examines if the mandate meaningfully increased coverage and what can be learned from the ACA if policymakers want to achieve universal coverage in the future.
-
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Categorized in -
Remanding Texas v. U.S. to the Lower Court Prolongs Harms to Consumers and the Health Care Industry
How will remanding Texas v. U.S. case to the lower court will affect the health care market? Drug manufacturers face tremendous scientific uncertainty while ACA funding has clearly become a major component in state spending.
-
Provider Charges Relative to Medicare Rates, 2012-2017
Researchers examined data on charges for providers treating Medicare patients and compared them to Medicare’s set payment rate across specialties. They found specialties possessing the ability to surprise bill out-of-network patients higher charges relative to Medicare rates than other specialties.